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Abstract
Background: Diagnosing heart failure and left ventricular systolic dysfunction is difficult on clinical
grounds alone. We sought to determine the accuracy of a heart failure register in a single primary
care practice, and to examine the usefulness of b-type (or brain) natriuretic peptide (BNP) assay
for this purpose.
Methods: A register validation audit in a single general practice in the UK was carried out. Of 217
patients on the heart failure register, 56 of 61 patients who had not been previously investigated
underwent 12-lead electrocardiography and echocardiography within the practice site. Plasma was
obtained for BNP assay from 45 subjects, and its performance in identifying echocardiographic
abnormalities consistent with heart failure was assessed by analysing area under receiver operator
characteristic (ROC) curves.
Results: 30/217 were found to have no evidence to suggest heart failure on notes review and were
probably incorrectly coded. 70/112 who were previously investigated were confirmed to have
heart failure. Of those not previously investigated, 24/56 (42.9%) who attended for the study had
echocardiographic left ventricular systolic dysfunction. A further 8 (14.3%) had normal systolic
function, but had left ventricular hypertrophy or significant valve disease. Overall,
echocardiographic features consistent with heart failure were found in only 102/203 (50.2%). BNP
was poor at discriminating those with and without systolic dysfunction (area under ROC curve
0.612), and those with and without any significant echocardiographic abnormality (area under ROC
curve 0.723).
Conclusion:  In this practice, half of the registered patients did not have significant cardiac
dysfunction. On-site echocardiography identifies patients who can be removed from the heart
failure register. The use of BNP assay to determine which patients require echocardiography is not
supported by these data.
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Background
Heart failure is an increasingly prevalent condition, asso-
ciated with markedly reduced survival and quality of life
despite recent advances in management [1]. The preva-
lence of heart failure in the community is around 2%, and
a similar proportion has left ventricular systolic dysfunc-
tion (LVSD, an important precursor of heart failure) [2].
In 1996, estimated overall incidence rate for heart failure
in the general population was 4.4 per 1000 person-years
in men and 3.9 per 1000 person-years in women [3].
The associated frequent hospitalisations and long-term,
evidence-based pharmacological therapies render heart
failure a costly condition to treat: recently, heart failure
was estimated to account for almost 2% of total NHS
expenditure [4]. Given the costs, therefore, it is vital that
such patients are correctly identified. Unfortunately, it is
well recognised that diagnosing heart failure and LVSD
upon clinical grounds alone is beset with difficulties due
to the limited specificity and sensitivity of typical symp-
toms. Modern diagnostic criteria for heart failure stipulate
the need to identify objective evidence of cardiac dysfunc-
tion [5]. Indeed, in the United Kingdom, the National
Institute for Clinical Excellence (NICE) has recommended
confirmation of the presence of cardiac dysfunction using
echocardiography [6]. Moreover, planned service contrac-
tual changes should further encourage general practition-
ers to request such investigations.
Within primary care practices, the compilation of registers
recording the details of patients with a variety of chronic
diseases (including heart failure) is common. There is
likely to be much heterogeneity among patients placed
upon such a register. For example, patients discharged
from hospital are more likely to have had diagnostic
investigations, whereas community subjects, in whom
access to echocardiography might be limited, may have
been registered purely on the presence of symptoms or
their perceived improvement with diuretic treatment;
high false-positive rates for diagnosis of heart failure are
apparent in the latter group [7,8]. A further key recom-
mendation of the NICE guidelines for heart failure is that
historical diagnoses should be reviewed, and subse-
quently, only confirmed cases should receive recom-
mended treatment [6].
With limited community access to echocardiography, and
high volumes of requests for echocardiography within
hospitals, more practical (and cheaper) methods of iden-
tifying cardiac dysfunction are clearly attractive. Thus, the
usefulness of quantifying plasma levels of natriuretic pep-
tides has received much attention in recent years. These
markers are thought to be released from myocardium in
response to wall stretch, with levels correlating with sever-
ity of heart failure. Brain natriuretic peptide (BNP) meas-
urement is a valuable adjunct to clinical assessment in
distinguishing heart failure from non-cardiac causes of
acute dyspnoea in patients presenting to emergency care
[9,10]. However, its role in primary care is less clear [11].
Its use in exclusion of heart failure is advocated in the
NICE guidelines [6].
We aimed to assess the accuracy of diagnosis among a
sample of patients registered as having heart failure in a
single primary care practice. The feasibility of performing
portable echocardiography within the primary care site
and the potential value of BNP assay in this group were
also studied.
Methods
A register of all practice patients with a previous diagnosis
coded as heart failure (Read code G58) was compiled in
November 2003. A search of practice and hospital records
was done to identify patients who had already undergone
objective assessment of cardiac function by echocardiog-
raphy or other investigation. Patients who had not previ-
ously had any such investigation were invited to attend for
electrocardiography, venepuncture, and echocardiogra-
phy, all performed in one visit to the general practice.
Demographic data and previous medical history were
recorded by nursing staff, and current medications were
documented from current prescription records. Standard
12-lead ECG and blood pressure measurement was per-
formed by nursing staff. The presence of major (patholog-
ical Q-waves, left bundle branch block, LVH, atrial
fibrillation) and minor abnormalities (all other devia-
tions from normal) were recorded by two investigators
(GSB or MDS). Subjects underwent trans-thoracic
echocardiography performed by one of two investigators
(GSB or MDS) using portable equipment (Acuson
Cypress, Siemens). Left ventricular systolic function was
analysed qualitatively based upon standard parasternal
and apical views, with left ventricular systolic dysfunction
defined as left ventricular ejection fraction < 40%. Valvu-
lar regurgitation was assessed semi-quantitatively based
upon colour and continuous wave Doppler flow charac-
teristics. Regurgitant lesions of at least moderate severity
were considered significant. Mitral and aortic stenosis
were significant if mitral valve area was < 1.5 cm2 or aortic
valve gradient was > 20 mmHg, respectively. Echocardio-
grams were reported by GSB and MDS, consistent with the
local hospital-based clinical echocardiography service.
Following echocardiography, with patients still supine
and resting, non-fasting venous blood was taken into
EDTA tubes and refrigerated (4°C) overnight. The tubes
were transported to the local hospital laboratory for cen-
trifugation. Plasma was subsequently frozen at -80°C
prior to BNP immunochemiluminometric assay (ADVIABMC Cardiovascular Disorders 2007, 7:23 http://www.biomedcentral.com/1471-2261/7/23
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Centaur autoanalyser, Bayer Diagnostics). The intra-assay
coefficient of variation was 6.1% at 12.6 pmol/L, 3.2% at
118.0 pmol/L, and 4.0% at 474.5 pmol/L.
Ethical approval was obtained by the Sandwell Local Eth-
ics Committee.
Statistical analysis
Comparisons of normally and non-normally distributed
data were made using the Students t-test and Mann-Whit-
ney test, respectively. Categorical data were compared
using the χ2 test. For assessment of diagnostic perform-
ance of the BNP assay, receiver operator characteristic
(ROC) curves were constructed by plotting sensitivity ver-
sus 1-specificity. A cut-off that provided the best combina-
tion of sensitivity and specificity was ascertained, and
negative (NPV) and positive (PPV) predictive values were
calculated for this level. P values < 0.05 were deemed to
indicate statistical significance. Data were analysed using
SPSS version 10.0 for Windows.
Results
217 patients were registered with a previous diagnosis of
heart failure (see Figure 1). Upon careful review of prac-
tice records, 30 patients did not have any symptomatic or
other evidence supporting a diagnosis of heart failure, and
these patients were removed from the register. Ten
patients were considered too unfit or unwell to attend the
practice, whilst a further four patients died between com-
pilation of the register and the next step of the study. Of
the remaining 173 patients, 112 had a record of previous
heart failure investigations. 70 of these patients had
echocardiography reports consistent with heart failure
whereas echocardiography in 39 patients had not sup-
ported the diagnosis of heart failure. One patient was con-
sidered unlikely to have heart failure due to a documented
normal ECG and chest X-ray. We were unable to trace
results of two patients. Of the remaining 61, 56 agreed to
attend for further investigations.
The mean age of the 56 patients attending for echocardi-
ography was 77 years (range 54–99), and 30/56 (53.6%)
were female. Baseline characteristics of the patients are
presented in Table 1. 24 (42.9%) were found to have
Table 1: Baseline characteristics of patients with and without echocardiographic abnormality indicative of heart failure
Echocardiogram not consistent 
with heart failure (n = 24)
Echocardiogram consistent with 
heart failure (n = 32)
p value
Age – mean (SD) 75.4 (7.2) 78.3 (8.4) 0.184 (t-test)
Male gender 13 (54.2%) 13 (40.6%) 0.315
Ischaemic heart disease 7 (29.2%) 16 (50.0%) 0.117
Hypertension 12 (50.0%) 14 (43.8%) 0.643
Diabetes 4 (16.7%) 9 (28.1%) 0.315
Atrial fibrillation 3 (12.5%) 6 (18.8%) 0.529
Peripheral vascular disease 2 (8.3%) 2 (6.3%) 0.765
Chronic airflow limitation 6 (25.0%) 5 (15.6%) 0.382
Diuretic 21 (87.5%) 24 (75.0%) 0.244
Angiotensin converting enzyme 
inhibitor or Angiotensin receptor 
blocker
14 (58.3%) 23 (71.9%) 0.290
Beta-blocker 2 (8.3%) 8 (25.0%) 0.107
Statin 9 (37.5%) 14 (43.8%) 0.638
Abnormal ECG 13 (54.2%) 27 (84.4%) 0.013
BNP (pmol/l) median (interquartile 
range)
11.7 (20.0) 32.75 (35.8) 0.010 (Mann-Whitney test)
Note – values are number (percentage) unless stated. P values refer to chi-squared tests unless stated.
Flow diagram for the 217 patients from the heart failure reg- ister Figure 1
Flow diagram for the 217 patients from the heart failure reg-
ister.BMC Cardiovascular Disorders 2007, 7:23 http://www.biomedcentral.com/1471-2261/7/23
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LVSD. A further eight (14.3%) had normal systolic func-
tion, but had an additional echocardiographic diagnosis
(left ventricular hypertrophy, or significant valve disease),
consistent with a diagnosis of heart failure with preserved
systolic function. Isolated diastolic dysfunction, in the
absence of systolic dysfunction, valve disease or left ven-
tricular hypertrophy, was not specifically examined for.
The groups were similar in age and gender. Patients with
echocardiography consistent with heart failure appeared
more likely to have a past medical history of ischaemic
heart disease, although this was not statistically signifi-
cant. Of note, only 5 patients with echocardiography con-
sistent with heart failure had a normal ECG, whereas 11
patients in whom heart failure was excluded had a normal
ECG. Therefore the positive predictive value of an abnor-
mal ECG was 0.68, whilst the negative predictive value
was 0.69.
Overall, objective evidence for a diagnosis of heart failure
was confirmed in only 102 (50.2%) of those on the prac-
tice register (excluding the 14 who died or were too
unwell to take part).
Blood sampling was performed in 45 patients who
attended for echocardiography. BNP was significantly
higher in the patients with echocardiographic features
consistent with heart failure, although in both groups the
median BNP was lower than that seen in acute heart fail-
ure, and even in those with echocardiographic features
consistent with heart failure the median BNP was similar
to the cut-off proposed for ruling out heart failure in
acutely breathless patients or untreated clinic patients
(29pmol/l) [12]. The distribution of BNP results for those
with and without echocardiographic abnormality is
shown in Figure 2. ROC curve analysis showed BNP to be
a poor discriminator between those with and without left
ventricular systolic dysfunction (area under the curve
0.612, Figure 3A). A larger area under the curve was found
when left ventricular systolic dysfunction and other
Receiver operating characteristic curves for BNP Figure 3
Receiver operating characteristic curves for BNP. A. Discrimination of those with and without left ventricular systolic 
dysfunction B. Discrimination of those with and without left ventricular systolic dysfunction or other significant echocardio-
graphic abnormality C. Discrimination of those with and without left ventricular systolic dysfunction or other significant 
echocardiographic abnormality or atrial fibrillation.
Distribution of BNP results in patients with and without  echocardiographic abnormality indicative of heart failure Figure 2
Distribution of BNP results in patients with and with-
out echocardiographic abnormality indicative of 
heart failure. Reference line at 29pmol/l indicates cutoff 
below which heart failure is ruled out in patients with acute 
shortness of breath in previous studies.[9]BMC Cardiovascular Disorders 2007, 7:23 http://www.biomedcentral.com/1471-2261/7/23
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echocardiographic abnormalities (significant valve dis-
ease or left ventricular hypertrophy) were considered
(area 0.723, Figure 3B), and when those with atrial fibril-
lation (who ideally require echocardiographic examina-
tion anyway [13]) who had not already been included
were added in to the model (area 0.750, Figure 3C).
Discussion
Summary of main findings
On a first 'trawl' of practice records, there appeared to be
several (30, 13.8%) patients who were wrongly placed
upon the heart failure register. For example, these patients
may have complained of mild peripheral oedema alone
or dyspnoea responsive to bronchodilators. Initially, it
appeared that many patients had never undergone
echocardiography or other diagnostic imaging. However,
over half (112/203) were found to have undergone
echocardiography when all patients' correspondence and
hospital databases had been searched. Most such patients
will not need to have repeated echocardiography per-
formed if registers are to be validated, so a comprehensive
record search, although labour-intensive, is likely to be
very useful. Notably, 40 patients remained on the register
despite documented investigations showing no cardiac
dysfunction.
We were able to identify 61 patients labelled with heart
failure but with no record of objective investigations to
confirm or refute the diagnosis. Many of these patients
were taking heart failure drugs, although the evidence
base for many of these drugs in heart failure is only for
those with left ventricular systolic impairment. Drugs
such as vasodilators and diuretics rapidly lower BNP in
patients with acute heart failure [14], and angiotensin
converting enzyme inhibitors [15] and beta-blockers [16]
lower BNP in patients with chronic heart failure, and so
the difference in BNP between patients with and without
left ventricular systolic dysfunction in our study might
have been greater if tested prior to commencing anti-fail-
ure medication. Ideally, all patients with a label of heart
failure would undergo echocardiography to identify those
with left ventricular systolic dysfunction, or significant
valvulopathy. However, echocardiography is time con-
suming and requires expensive equipment and highly
trained operators. BNP is attractive as a method of select-
ing a subgroup of patients who require echocardiography,
but our data do not support the use of this test in this set-
ting.
Comparison with existing literature
One previous study of 100 stable patients with a label of
heart failure in a general practice setting also concluded
that BNP was of limited value in the diagnosis of left ven-
tricular systolic dysfunction in this situation [11]. A sec-
ond study, using N-terminal pro-BNP rather than BNP
reported a similar area under the receiver operating char-
acteristic curve (0.8) for the identification of left ventricu-
lar systolic dysfunction in a general practice population
with a label of heart failure (n = 103) [17]. Natriuretic
peptides may be useful in assisting diagnosis of patients
with symptoms of heart failure at first presentation to
their general practitioner, before they are commenced on
treatments that might lower BNP [18,19]. Further studies
would be necessary to confirm this possibility.
Strengths and the limitations of this study
Performing portable echocardiography within a primary
care site was found to be feasible, and particularly appeal-
ing to many of the elderly patients who lived considerable
distances from secondary care centres. Furthermore,
blood testing was undertaken at the practice, with samples
refrigerated overnight prior to transportation for centrifu-
gation and freezing prior to batch testing. It is possible
that there may be some deterioration in BNP levels with
such an approach, however our intention was to replicate
the likely situation should BNP assays become a routine
primary care test. Had we centrifuged and frozen the sam-
ple immediately, the performance of BNP might have
been enhanced, but the results would not then have been
applicable to the 'real world'. A similar approach to that
used in our study was used in a multicentre study of BNP
levels in patients with heart failure [20]. We recognise that
this study was of limited size, being performed in a single,
albeit large, general practice. Detailed study of left ven-
tricular diastolic function was not done as part of the
echocardiograms. However, left ventricular hypertrophy,
a common cause of diastolic heart failure, is reported on.
We felt it most appropriate to concentrate on left ventricu-
lar systolic dysfunction, to which the NICE guideline [6]
and most of the evidence base in heart failure applies.
Implications for clinical practice
We cannot support the use of BNP testing in validation of
general practice heart failure registers. If access to BNP
testing for general practitioners – as advocated in the
NICE heart failure guidelines – becomes widespread, it is
important to appreciate that the test is not likely to be use-
ful in patients with a label of heart failure who are already
on treatment. A normal ECG, however, retains its negative
predictive value for systolic dysfunction.
Conclusion
Heart failure is difficult to diagnose and NICE guidelines
advocate confirmation of diagnoses made previously.
Only half of those patients registered as having heart fail-
ure in a primary care practice had the diagnosis validated
by on-site echocardiography. Plasma BNP assay did not
appear to be a useful tool for retrospective diagnostic val-
idation in patients already on treatment for heart failure.BMC Cardiovascular Disorders 2007, 7:23 http://www.biomedcentral.com/1471-2261/7/23
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